THERAPY DOSSIER · th-f3dd3ced0193

Racemic nilvadipine and the (-)-nilvadipine enantiomer ARC031

Drug · Dihydropyridine L-type calcium channel blocker.

Evidence & regulatory context

Mechanism: Dihydropyridine L-type calcium channel blocker.
Target: CHEMBL2095229 (L-type Ca channel)
Injury models: TBI
Reported indication: Not recorded
First approval: Not recorded
Development stage: In trials, not approved
ChEMBL record: CHEMBL517427 ↗
ChEMBL max phase: 3 / 4 (development scale, not regulatory approval)
Synonyms: Nivadil; FK-235; ARC031 (enantiomer)
Note: Not recorded

Clinical trials 1

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT02017340 ↗PHASE3completed

Nilvadipine in Mild to Moderate Alzheimer's Disease (Phase III)

Alzheimer's Disease

Enrolment: 511 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 33076989 ↗2020Mixed findings

Nilvadipine suppresses inflammation via inhibition of P-SYK and restores spatial memory deficits in a mouse model of repetitive mild TBI.

MouseTBIClosed-head / concussionhTauMale and femalen = 72 mice, n = 12 per group across six groups; tau immunoassa…Intraperitoneal2 mg/kg in 100 uLFirst dose immediately after the last injury, while still anaesthetised

Model: Repetitive mild TBI, five closed-head impacts at 48 h intervals, 3 mm blunt tip, 5 m/s, 1.0 mm depth, 200 ms dwell

Racemic nilvadipine improved motor and spatial memory deficits and reduced astrogliosis, microgliosis, CD68 and P-SYK, whereas ARC031 improved memory and corpus callosum gliosis but not motor deficits or cortical astrogliosis.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.92. Machine-extracted fields require source verification.

Loading the evidence…